key: cord-0771412-3xz4hecb
authors: Raiker, R.; Pakhchanian, H.; Hussain, A.; Deng, M.
title: 331 Trends and outcomes in patients with malignant skin cancers during the COVID pandemic
date: 2021-05-31
journal: Journal of Investigative Dermatology
DOI: 10.1016/j.jid.2021.02.353
sha: 12bfaf9ba0b9561d955f6a2ae99a82a3e209ccd0
doc_id: 771412
cord_uid: 3xz4hecb

nan

Data driven approach identifies hidradenitis suppurativa subtypes in electronic health records A Bell 1 , K Babbush 3 , A Khan 1 , M Hayes 2 , J Connolly 4 , F Mentch 4 , P Sleiman 4,5 , H Hakonarson 4,5 , E Mukherjee 6 , G Hripcsak 1 , K Kiryluk 1 , C Weng 1 , S Cohen 3 , L Wheless 6 and L Petukhova 1 1 Columbia University, New York, New York, United States, 2 Northwestern University, Chicago, Illinois, United States, 3 Albert Einstein/Montefiore, Bronx, New York, United States, 4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 5 University of Pennsylvania, Philadelphia, Pennsylvania, United States and 6 Vanderbilt University, Nashville, Tennessee, United States Hidradenitis suppurativa (HS) is a prevalent inflammatory skin disease that is associated with a high burden of comorbidities. Heterogeneity in clinical presentation coupled with variation in treatment response suggests that among people who share an HS diagnosis there exist different biological causes of disease. Obscure etiological heterogeneity creates inefficiencies in healthcare and attenuates power in clinical trials and research studies. While previous studies have attempted to identify HS subtypes on the basis of characteristics primarily related to skin lesions, our group hypothesizes that distributions of comorbidities can be used to identify medically relevant HS subtypes. We implemented machine learning algorithms to investigate comorbidity patterns using longitudinal data from the eMERGE consortium (project NT227) that contains 368,331 diagnosis codes from 668 HS participants capturing on average 16 years of observations per person. Using a tensor factorization (TF) method we identified five disease subtypes characterized by the onset of different sets of diseases prior to an initial HS diagnosis, including (1) neuropsychiatric, (2) joint, (3) metabolic, (4) cardiopulmonary, or (5) obesity and acne. We next leveraged the feature weighting scheme identified by TF to develop subtype phenotype scores (SPS) for research participants. Unsupervised clustering of participant SPS in the eMERGE cohort and in an independent cohort both indicate that most HS participants can be assigned to a single subtype. This work suggests that patterns of HS comorbidities can be used to identify disease subtypes. Future studies are aimed at determining the biological and clinical relevance of our work.

Efficacy of ruxolitinib cream in adults and adolescents with atopic comorbidities E Simpson 1 , M Lee 2 , KK Brar 3 , ME Kuligowski 4 , ME Venturanza 4 , K Sun 4 and D Atopic dermatitis (AD) is an inflammatory skin disease associated with atopic and nonatopic comorbidities. Efficacy outcomes in patients with or without atopic comorbidities from a pooled analysis of two phase 3 studies (TRuE-AD1 [NCT03745638], TRuE-AD2 [NCT03745651]) in 1208 evaluable patients (!12 y) with AD for !2 y with Investigator's Global Assessment (IGA) score 2 or 3 and 3%e20% affected body surface area are reported. Patients (N¼1249) were randomized (2:2:1) to twice-daily 0.75% or 1.5% ruxolitinib cream (RUX; Janus kinase [JAK] 1/JAK2 inhibitor) or vehicle cream for 8 weeks. Outcome measures included the percentage of patients achieving IGA treatment success (IGA-TS; IGA of 0/1 and !2-grade improvement vs baseline); !50%, !75%, and !90% improvement in Eczema Area and Severity Index (EASI-50, -75, and -90, respectively) vs baseline; and a !4-point improvement in itch Numerical Rating Scale score (NRS4). Overall, 51.1% of efficacyevaluable patients had atopic comorbidities at baseline. At Week 8, among patients with comorbidities, substantially more who applied RUX (0.75%/1.5%) vs vehicle achieved IGA-TS (50.4%/57.4% vs 10.5%), EASI-50 (75.8%/82.1% vs 33.3%), EASI-75 (58.3%/67.7% vs 19.3%), EASI-90 (42.5%/50.6% vs 5.3%), and NRS4 (47.0%/55.5% vs 9.9%). Greater mean change (reduction) from baseline in itch NRS scores occurred within 12 h of first application of RUX vs vehicle (À0.4/À0.4 vs À0.1). Similar results were observed among patients without comorbidities. In summary, patients with AD treated with RUX cream had markedly improved AD signs and symptoms (itch relief within hours of first application) regardless of atopic comorbidities.

Smoking cessation is significantly correlated with disease manifestation in Pemphigus vulgaris HK Shaik, K Seiffert-Sinha and AA Sinha Dermatology, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York, United States Pemphigus vulgaris (PV) is a potentially fatal autoimmune blistering skin disease characterized by the prominence of anti-desmosomal antibodies anti-desmoglein 3 and 1 leading to intraepidermal blistering. However, other antibodies including those targeting acetylcholine receptors have also been implied in disease. The etiology of PV is multifactorial with a strong genetic association with certain HLA alleles, but it is clear that additional environmental and immune trigger factors are needed to induce disease. Among these trigger factors, an inverse relationship between smoking and PV has been noted in several case-control studies, i.e. PV occurs less frequently in current and former smokers when compared to controls. It has been speculated that the putative protective action of smoking is due to the anti-acantholytic action of triggering acetylcholine receptors by their agonist nicotine. However, no study to date has directly addressed the temporal relationship between smoking and disease, specifically whether patients with a history of smoking ceased to smoke before or after disease onset. Thus, we designed a study in which patients with a biopsy confirmed diagnosis of PV were asked whether they had a history of smoking and whether they quit smoking before or after disease onset in addition to other constant and variable disease parameters. Out of 78 PV patients and 38 age-and sex-matched controls, approximately 50% were former or current smokers in both groups. Of the former/current smokers in the PV group, however, 94% of patients quit smoking before study inclusion, with 81% quitting before the onset of disease, while in the control group only 56% of subjects quit smoking before enrollment (OR 0.59 and 0.69; 95% CI 0.24-1.45 and 0.28-1.72, respectively). Our data suggests that it is not the mere absence of smoking, but the lack of smoking-associated molecules (presumably nicotine) in subjects previously exposed to these molecules (in other words, smoking cessation), that can be considered to be a trigger factor in PV. The COVID-19 pandemic has forced healthcare organizations to reduce the provision of nonemergent services leading to delays in diagnoses and treatment. There is scant literature regarding the impact of COVID in malignant skin cancer (MSC) patients. A retrospective analysis was done from Apr-July 2020 using TriNetX, a national federated database of 63 million records. The incidence of new MSC-related codes was estimated during the pandemic period and compared to a corresponding pre-pandemic period. Medical encounter visits utilized by MSC patients during the pandemic was also recorded. 30-day COVID complications were compared among COVID patients with and without history of confirmed MSC. 1:1 propensity score matching for comorbidities and demographics was performed to estimate adjusted risk ratios with 95% CI. Kaplan Meir's (KM) analysis was done to calculate survival probability in 30 days among the matched cohorts. The incidence of malignant melanoma, malignant nonmelanoma skin cancers (NMSC), and overall MSC dropped by 40%(p¼0.001), 48%(p<0.001), and 53%(p¼0.001) respectively when compared to a similar pre-pandemic period. Skin cancer screenings dropped by 37%(p¼0.04). Telehealth services utilized by MSC patients increased from 100 encounters total in 2018 to 23279 encounters from Jan-July 2020. After matching, COVID-19 patients with a history of MSC had a significantly lower risk of hospitalization (RR The COVID19 pandemic has caused a major disruption in healthcare delivery as restrictions have limited the ability to seek elective procedures. This investigation aimed to assess the pandemic impact on the incidence of dermatology procedures compared to the prepandemic period. TrinetX, a national federated healthcare database comprised of 61 million patient records, was used to identify the incidence of new dermatology procedures performed each month for two periods of the pandemic. The first period was from Apr-July 2020, and the second was from Aug-Nov 2020. The mean for each variable was then compared with the pooled monthly incidence from similar periods between 2018-2019 before the pandemic. Descriptive analyses were performed, and comparisons were made using a student's t-test. Procedures were identified by CPT codes and categorized into groups. In the Apr-July 2020 period, 11 groups of procedures showed a significant statistical decrease in incidence by up to 47.3%. They included: Excision of benign lesions, shaving of epidermal/dermal lesions, skin tag removal, skin biopsy, paring/cutting procedures, surgical procedures on nails, surgical procedures on pilonidal cyst, destruction of malignant lesions, destruction of benign/ premalignant lesions, Mohs surgery, and incision and drainage procedures. The incidence of debridement procedures during the initial COVID period was similar to overlapping months in 2018 and 2019. In the late pandemic period, 10 procedure groups demonstrated a significant statistical decrease in incidence. The incidence of debridement procedures and surgical procedures on pilonidal cysts during the later COVID period was similar to overlapping months in 2018 and 2019. The statistically significant decrease in dermatology procedures during the COVID-19 pandemic may suggest that the general public is postponing skin care placing a greater burden on healthcare.

Independent sample ttests compared uncontrolled vs controlled patients. Of 575 patients (424 adults/151 adolescents 12-17 yrs), 398 (69%) received topicals only (TOP) and 140 (24%) received topicals with a systemic (steroid, immunosuppressant or biologic) (T+S) for at least a month. On TOP, 21% of adults and 24% of adolescents were uncontrolled, rising to 26% and 50%, respectively, on T+S. This aligned with physicians being dissatisfied with control achieved for 27-31% of adults and 40-50% of adolescents, for TOP/T+S, respectively. For adults/adolescents, respectively, receiving TOP: POEM scores were 7WPAI, % overall work impairment scores for adults receiving TOP: controlled 13